A scoping review published in Breast Cancer Research argues that exercise may be a subtype-specific supportive care strategy for triple-negative breast cancer (TNBC), an aggressive form of the disease with limited therapeutic options beyond conventional chemotherapy. The review, authored by Hae Sung Lee, Joon Kim, and Yae-Young Kim, synthesizes evidence on exercise-induced biological mechanisms, clinical outcomes, and implementation strategies for patients with TNBC.
The authors’ central proposition is mechanistic rather than a demonstrated clinical effect. TNBC is characterized by molecular features that include immune evasion, constitutive inflammatory signaling, and hyperactivated PI3K/Akt/mTOR signaling. The review suggests these vulnerabilities may plausibly align with the biological adaptations induced by exercise, offering a rationale for why exercise could be biologically distinct in TNBC compared with hormone receptor-positive disease. The authors emphasize this remains a hypothesis to be tested, not an established treatment effect.
Several exercise-linked pathways with potential anti-tumor relevance are described. These include myokine-mediated activation of natural killer cells, inhibition of the AMPK/mTOR pathway, suppression of nuclear factor-kappa B signaling, and epigenetic modifications. Preclinical and translational studies further suggest that exercise-induced circulating factors may suppress TNBC cell growth in laboratory models and enhance anti-tumor immunity. The review is careful to note that clinical replication of these findings in TNBC-specific patient populations remains limited, and laboratory findings cannot be read as proven benefits for patients.
On the clinical side, the review highlights emerging evidence that aerobic and resistance training may improve quality of life, reduce cancer-related fatigue, help preserve physical function, and support maintenance of chemotherapy dose intensity in some patient subgroups. These observations are drawn from studies of varying design and are characterized by the authors as preliminary rather than definitive.
The most concrete clinical evidence cited comes from a randomized controlled trial of aerobic and resistance training delivered during neoadjuvant chemotherapy. That trial enrolled 180 participants and included hormone receptor-negative patients, a group that encompasses TNBC. Both exercise modalities significantly reduced premature chemotherapy discontinuation, and no severe exercise-related adverse events were reported in the trial. The authors describe this as preliminary support for the short-term safety, feasibility, and clinical relevance of supervised exercise during active chemotherapy.
Because the trial population included hormone receptor-negative patients broadly rather than a TNBC-only cohort, its findings cannot be attributed exclusively to triple-negative disease. The review nonetheless treats dose intensity preservation as a clinically meaningful endpoint, since premature chemotherapy discontinuation can compromise treatment delivery.
Significant gaps remain. The authors state that evidence is limited for patients with metastatic disease and for long-term oncologic outcomes such as survival and recurrence. Most mechanistic support comes from preclinical work, and the proposed alignment between TNBC biology and exercise adaptations has not been confirmed in TNBC-specific clinical trials.
To address these gaps, the review calls for TNBC-targeted trials designed with immune and metabolic biomarkers as primary outcome domains. Such studies would allow researchers to test directly whether the molecular pathways identified in laboratory and translational work translate into measurable biological and clinical effects in patients with triple-negative breast cancer.
The article is published as an open access review and was made available early as a peer-reviewed, accepted manuscript carrying a permanent DOI, with a final version of record to follow. As a scoping review, it maps and synthesizes existing research rather than presenting new experimental data, and its conclusions about exercise in TNBC should be understood as a research agenda grounded in preliminary evidence.
Subject of Research: Exercise intervention as a supportive care strategy in triple-negative breast cancer
Article Title: From sedentary to survival: exercise intervention as a precision supportive care strategy in triple-negative breast cancer—a scoping review
Article References: Lee, H. S., Kim, I., & Kim, Y.-Y. (2026). From sedentary to survival: exercise intervention as a precision supportive care strategy in triple-negative breast cancer—a scoping review. Breast Cancer Research. https://doi.org/10.1186/s13058-026-02357-x
Image Credits: AI Generated
DOI: 10.1186/s13058-026-02357-x
Keywords: triple-negative breast cancer, exercise intervention, scoping review, chemotherapy, supportive care, myokines, natural killer cells, AMPK/mTOR, dose intensity, randomized controlled trial, anti-tumor immunity, physical function
News Source: Nathaniel Bowman. (October 30, 2026). Exercise Shows Early Safety Signals During Triple-Negative Breast Cancer Chemotherapy. Scienmag.
